If this proposed molecular mechanism is correct, one would speculate that the retargeting of the CFTR at the apical plasma membrane by the specific anti-inflammatory treatment will restore pancreatic HCO3- secretion in chronic pancreatitis, and prevent pancreatic stone formation in chronic pancreatitis. Here, CFTR is linked to chronic pancreatitis.